Araris Biotech

Executive Summary

Araris Biotech AG, a Swiss spin-off from the Paul Scherrer Institute and ETH Zurich, is developing a proprietary antibody-drug conjugate (ADC) linker technology that enables rapid, one-step attachment of payloads to off-the-shelf antibodies without the need for antibody re-engineering or reduction. This approach yields highly homogeneous, stable, and potent ADC therapies, addressing key limitations of conventional conjugation methods that produce heterogeneous mixtures and require complex engineering. Founded in 2019 and currently in the pre-clinical stage, Araris aims to expand the therapeutic window of ADCs and improve patient outcomes. The company's platform has the potential to generate a pipeline of best-in-class ADCs across multiple oncology indications. Araris is private and has not disclosed funding details to date. With a strong intellectual property position and a first-in-class linker technology, the company is well-positioned to attract partnerships and advance its own candidates toward clinical development. The innovative platform could significantly impact the ADC landscape, offering a versatile and efficient solution for creating next-generation antibody-drug conjugates.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate Nomination and Preclinical Data Release70% success
• H1 2027Strategic Partnership or Licensing Deal with Major Pharma60% success
• Q2 2027IND-Enabling Studies Initiation50% success